GLATIRAMER vs TERIFLUNOMIDE

Compare GLATIRAMER (Glatiramer Acetate) and TERIFLUNOMIDE (Teriflunomide) — clinical data, side effects, and patient experiences.

GLATIRAMER

Glatiramer Acetate · Other

How it works

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act...

Approved for

1 INDICATIONS AND USAGE Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

SubcutaneousTablet

TERIFLUNOMIDE

Teriflunomide, Aubagio · DMARD

How it works

12.1 Mechanism of Action Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de no...

Approved for

1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

OralTablet

Quick Comparison

GLATIRAMERTERIFLUNOMIDE

Drug Class

Other

DMARD

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GLATIRAMER

Injection Site Pain

>10%

Drug Not Working

1-10%

Injection Site Reaction

1-10%

Fatigue

1-10%

Shortness of Breath

1-10%

Falls

1-10%

Nausea

0.1-1%

Dizziness

0.1-1%

TERIFLUNOMIDE

Hair Loss

>10%

Fatigue

1-10%

Diarrhea

1-10%

Falls

1-10%

Headache

1-10%

Drug Not Working

1-10%

Tingling/Numbness

1-10%

Nausea

1-10%

FDA Warnings

GLATIRAMER

5 WARNINGS AND PRECAUTIONS • Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting ( 5
6 ) • Glatiramer Acetate Products and Administration Errors: Using an optional autoinjector that is not compatible for use with Mylan’s glatiramer acetate injection may increase the risk for medication errors, such as dose omission or administration of a partial dose
1 Anaphylactic Reactions Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection [see Adverse Reactions (6
Glatiramer acetate injection is contraindicated in patients with a history of hypersensitivity reactions to glatiramer acetate injection, including anaphylaxis [see Contraindications (4) ]

TERIFLUNOMIDE

5 WARNINGS AND PRECAUTIONS • Elimination of teriflunomide tablets can be accelerated by administration of cholestyramine or activated charcoal for 11 days
Consider suspending treatment with teriflunomide tablets in case of serious infection
Patients with pre-existing liver disease and patients taking other hepatotoxic drugs may be at increased risk for developing liver injury when taking teriflunomide tablets
Teriflunomide tablets are contraindicated in patients with severe hepatic impairment [see Contraindications (4) ]

Clinical Trial Data

No head-to-head clinical studies found for GLATIRAMER vs TERIFLUNOMIDE.

GLATIRAMER vs TERIFLUNOMIDE: What You Should Know

Key Differences

GLATIRAMER is a Other, while TERIFLUNOMIDE belongs to the DMARD class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. GLATIRAMER is administered via Subcutaneous, whereas TERIFLUNOMIDE uses Oral. Route of administration can affect onset of action and patient adherence.

Shared Indications

Both medications are approved for to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, to include clinically isolated syndrome. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

GLATIRAMER carries 4 FDA warnings. TERIFLUNOMIDE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LEFLUNOMIDE vs TERIFLUNOMIDE→HYDROXYCHLOROQUINE SULFATE vs TERIFLUNOMIDE→METHOTREXATE vs TERIFLUNOMIDE→Hydroxychloroquine vs TERIFLUNOMIDE→DIMETHYL FUMARATE vs TERIFLUNOMIDE→DIMETHYL FUMARATE vs GLATIRAMER→

Loading comparison data...

GLATIRAMER vs TERIFLUNOMIDE

Compare GLATIRAMER (Glatiramer Acetate) and TERIFLUNOMIDE (Teriflunomide) — clinical data, side effects, and patient experiences.

GLATIRAMER

Glatiramer Acetate · Other

How it works

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act...

Approved for

1 INDICATIONS AND USAGE Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

SubcutaneousTablet

TERIFLUNOMIDE

Teriflunomide, Aubagio · DMARD

How it works

12.1 Mechanism of Action Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de no...

Approved for

1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

OralTablet

Quick Comparison

GLATIRAMERTERIFLUNOMIDE

Drug Class

Other

DMARD

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GLATIRAMER

Injection Site Pain

>10%

Drug Not Working

1-10%

Injection Site Reaction

1-10%

Fatigue

1-10%

Shortness of Breath

1-10%

Falls

1-10%

Nausea

0.1-1%

Dizziness

0.1-1%

TERIFLUNOMIDE

Hair Loss

>10%

Fatigue

1-10%

Diarrhea

1-10%

Falls

1-10%

Headache

1-10%

Drug Not Working

1-10%

Tingling/Numbness

1-10%

Nausea

1-10%

FDA Warnings

GLATIRAMER

5 WARNINGS AND PRECAUTIONS • Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting ( 5
6 ) • Glatiramer Acetate Products and Administration Errors: Using an optional autoinjector that is not compatible for use with Mylan’s glatiramer acetate injection may increase the risk for medication errors, such as dose omission or administration of a partial dose
1 Anaphylactic Reactions Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection [see Adverse Reactions (6
Glatiramer acetate injection is contraindicated in patients with a history of hypersensitivity reactions to glatiramer acetate injection, including anaphylaxis [see Contraindications (4) ]

TERIFLUNOMIDE

5 WARNINGS AND PRECAUTIONS • Elimination of teriflunomide tablets can be accelerated by administration of cholestyramine or activated charcoal for 11 days
Consider suspending treatment with teriflunomide tablets in case of serious infection
Patients with pre-existing liver disease and patients taking other hepatotoxic drugs may be at increased risk for developing liver injury when taking teriflunomide tablets
Teriflunomide tablets are contraindicated in patients with severe hepatic impairment [see Contraindications (4) ]

Clinical Trial Data

No head-to-head clinical studies found for GLATIRAMER vs TERIFLUNOMIDE.

GLATIRAMER vs TERIFLUNOMIDE: What You Should Know

Key Differences

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.